Communiqués Alector, Inc.

Actions

ALEC

US0144421072

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 09/10/2026			Varia. 5j.	Varia. 1 janv.
2,080 ^USD	+2,97 %		+14,92 %	+33,33 %

05/10	Les actions d’Alector progressent après la cession sous licence du programme AL050 à Genentech, filiale de Roche	MT
05/10	Alector, Inc. et Genentech, Inc. concluent un accord de licence mondial portant sur un traitement enzymatique substitutif par glucocérébrosidase (GCase) capable de pénétrer dans le cerveau pour la maladie de Parkinson et d’autres maladies neurodégénératives	CI

Communiqués

07/10	Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline	GL
05/10	Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases	GL
03/09	Alector to Participate in Upcoming Healthcare Conferences	GL
07/08	Alector : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU
06/08	Alector: Q2 Earnings Snapshot	AQ
06/08	Alector Reports Second Quarter 2026 Financial Results and Provides Business Update	GL
08/05	Alector : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Alector: Q1 Earnings Snapshot	AQ
07/05	Alector Reports First Quarter 2026 Financial Results and Provides Business Update	GL
29/04	Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis	GL
25/03	Alector : March 2026 Corporate Presentation	PU
25/02	Alector : February 2026 Corporate Presentation	PU
25/02	Alector: Q4 Earnings Snapshot	AQ
25/02	Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update	GL
24/02	Alector to Participate in the TD Cowen 46th Annual Health Care Conference	GL
03/02	Alector : February 2026 Update	PU
30/01	Levi & Korsinsky is Investigating Alec Stock After its Phase 3 INFRONT-3 Clinical Trial Misses Co-Primary Endpoint	PR
07/01	Alector : January 2026 Corporate Presentation	PU
12/12	Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer	GL
01/12	Alector to Participate in the Bank of America CNS Therapeutics Conference	GL
06/11	Alector : November 2025 Corporate Presentation	PU
06/11	Alector: Q3 Earnings Snapshot	AQ
06/11	Alector Reports Third Quarter 2025 Financial Results and Provides Business Update	GL
06/11	Alector Reports Third Quarter 2025 Financial Results and Provides Business Update	AQ
21/10/25	Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update	GL